Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Bruna Cipriano Almeida Barros"'
Autor:
Mayara Costa de Camargo, Bruna Cipriano Almeida Barros, Izabela Fulone, Marcus Tolentino Silva, Miriam Sanches do Nascimento Silveira, Iara Alves de Camargo, Silvio Barberato-Filho, Fernando de Sá Del Fiol, Luciane Cruz Lopes
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Biological agents used for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are associated with serious adverse effects (SAEs). Although several biologics have demonstrated good efficacy and tolerability in short-t
Externí odkaz:
https://doaj.org/article/79f0db69893148e68a20d20549cdc92e
Autor:
Rodolfo D. Cançado, Maylla Rodrigues Lucena, Vera Lúcia Nascimento Blaia-D Avila, Valdemir Melechco Carvalho, Christine M. Pfeiffer, Ralph Green, Guilherme Wataru Gomes, Elvira Maria Guerra-Shinohara, Bruna Cipriano Almeida Barros, Maria Stella Figueiredo, Clóvis Paniz, Zia Fazili, Juliano Felix Bertinato, Felipe Rebello Lourenço
Publikováno v:
Journal of investigative medicine : the official publication of the American Federation for Clinical Research, vol 67, iss 8
Patients with hereditary spherocytosis (HS) have increased rates of erythropoiesis and higher folate requirements. In a case-control study of patients with HS, we evaluated the associations between the use of 5 mg folic acid (FA) daily and serum conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5734e4820f54f1e163abee31584002aa
https://doi.org/10.1136/jim-2019-001025
https://doi.org/10.1136/jim-2019-001025
Autor:
Iara Alves de Camargo, Miriam Sanches do Nascimento Silveira, Mayara Costa de Camargo, Fernando de Sá Del Fiol, Silvio Barberato-Filho, Bruna Cipriano Almeida Barros, Marcus Tolentino Silva, Luciane Cruz Lopes, Izabela Fulone
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology, Vol 10 (2019)
Background: Biological agents used for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are associated with serious adverse effects (SAEs). Although several biologics have demonstrated good efficacy and tolerability in short-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bab46f29371076b7626062915393eab
https://pubmed.ncbi.nlm.nih.gov/31572173
https://pubmed.ncbi.nlm.nih.gov/31572173
Autor:
Iara Alves de Camargo, Luciane Cruz Lopes, Gordon Guyatt, Miriam Sanches do Nascimento Silveira, Bruna Cipriano Almeida Barros, Claudia Garcia Serpa Osorio-de-Castro
Publikováno v:
Clinical therapeutics. 38(5)
Purpose Biological agents used for the treatment of rheumatoid arthritis (RA) are associated with serious adverse events. Guidelines provide standards for the prescribing and monitoring of these drugs. In Sao Paulo, health litigation for access to me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f04fab97a61d4aeba720db13743f61
https://pubmed.ncbi.nlm.nih.gov/26976223
https://pubmed.ncbi.nlm.nih.gov/26976223